Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

On October 19, 2026, BMS said it will present 12 oral presentations and nearly 60 disclosures at ESMO, October 23–27 in Madrid, including late-breaking Phase 3 data for izalontamab brengitecan in EGFR-mutated NSCLC and HR+/HER2− breast cancer, and Phase 2 pumitamig data in metastatic NSCLC.